Threshold's Window of Success Reopens

Shares of Threshold Pharmaceuticals (NASDAQ: THLD  ) jumped up 15% today, bizarrely upon news that its competitor Celgene (NASDAQ: CELG  ) announced a set of successful phase 3 results. In this video, Motley Fool health-care analyst David Williamson tells investors what was behind this counterintuitive pop, and why it could be an excellent indicator for some of Threshold's own trials.

It's unusual to see a competitor's success bring a company's stock up, but that's what happened today with Threshold and Celgene. With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand-new premium report on Celgene. To claim your copy today, simply click here now.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2212150, ~/Articles/ArticleHandler.aspx, 12/22/2014 2:34:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement